Advanced searches left 3/3

Treatment of Cancer - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 12 March 2022

* If you want to update the article please login/register

Pilot Study of Ruxolitinib in the Treatment of Cancer Cachexia

Patients with Lung cancer on the whole, and a substantial number of NSCLC patients in particular, suffer with cancer cachexia. For the older patient population, a starting dose of 10 mg twice daily oral administration of ruxolitinib has been established, as well as a starting dose for the polycythemia patients, based on the findings of the REACH2 and REACH3 trials. Ruxolitinib has not been tested in 1 of 1 cancer cachexia patient populations in an evaluable trial or two in the establishment of first-line cancer therapies for solid tumors in patients receiving new care including immunotherapy IO. The use of ruxolitinib in patients with frequent tissue and serum samples will enable us to better understand how important JAK/STAT signaling is to clinical cancer cachexia development.

Source link: https://clinicaltrials.gov/ct2/show/NCT04906746


A Safety Lead-In/Randomized Phase 2 Study of BMX-001 as a Therapeutic Agent for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

The selected MTD of BMX-001 in patients with MBM under standard protocol WBRT will meet the "go/no-go" requirements for advancing to Phase 2. Phase 2 of a randomized open-label Phase 2 clinical trial of 64 patients with MBM, half receiving BMX-001 in combination with WBRT, and half receiving WBRT alone.

Source link: https://clinicaltrials.gov/ct2/show/NCT03608020

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions